


Patient Name:	Accession #:
MRN:	Case Accessioned:
DOB • Age • Sex:	Specimen Received:
Ordering Physician:	External Accession #:
Specimens Received	Documents Received

Results Summary

Left Middle Thyroid FNA
Nodule is very highly likely benign.



Test Results

Left Middle Thyroid FNA
ThyGenX™ Oncogene Panel Status: **No Mutations Detected**
ThyraMIR™ microRNA Classifier Status: **Negative**

Thyroid nodules showing indeterminate cytology with negative ThyGenX and negative ThyraMir status are highly likely to be benign (94% likelihood of being benign) (1)

Methods: DNA and RNA have been extracted from the thyroid nodule needle aspirate specimen provided. Using Next generation Sequencing technology, oncogene point mutations (KRAS, HRAS, NRAS, BRAF, PIK3CA) and gene rearrangement/translocations (RET/PTC1,3, PAX8/PPARGamma) were searched for (ThyGenX) and no mutations were detected. The expression level of a panel of microRNA markers capable of discriminating between benign versus malignant disease (ThyraMir) indicated negative status which, in this context, strongly supports benign status.

Because thyroid nodular disease can contain multifocal areas of heterogeneous pathology, sampling variation may occasionally result in under diagnosis of existing pathology. All decision factors, including ultrasound results, nodule size, and patient history need to be taken into account when determining treatment.

1. E. Labourier et al, Multi-categorical testing for miRNA, mRNA and DNA in fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology, Endocrine Reviews, 86(2), 2015

*Components of ThyGenX testing were performed at Interpace Diagnostics, 2 Church Street South, Suite B-05B, New Haven, CT 06519, USA.
ThyraMIR testing and the interpretive component of both tests was performed at Interpace Diagnostics, 2515 Liberty Ave, Pittsburgh, PA 15222, USA.*